Eligi
Med
Base de datos
Seguridad
Sobre EligiMed
Contacto
Contáctenos
Ensayos Clínicos de Endocrinología | EligiMed
Ensayos clínicos
694 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00789035
Completado
ClinicalTrials.gov
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
OBSERVATIONAL
Inicio: 5 de sept de 2012
ID: NCT01696266
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
INTERVENTIONAL
Inicio: 4 de jun de 2013
ID: NCT01809327
Completado
Fase 4
ClinicalTrials.gov
CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
INTERVENTIONAL
Inicio: 10 de jul de 2013
ID: NCT01897532
Completado
Fase 3
ClinicalTrials.gov
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
INTERVENTIONAL
Inicio: 29 de oct de 2013
ID: NCT01959529
Completado
Fase 3
ClinicalTrials.gov
2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.
INTERVENTIONAL
Inicio: 1 de jun de 2004
ID: NCT00184665
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure
INTERVENTIONAL
Inicio: 15 de jun de 2018
ID: NCT03521934
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
INTERVENTIONAL
Inicio: 5 de jun de 2023
ID: NCT05872620
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
INTERVENTIONAL
Inicio: 1 de jul de 2010
ID: NCT01131676
Completado
Fase 3
ClinicalTrials.gov
A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen
INTERVENTIONAL
Inicio: 1 de mar de 2002
ID: NCT01486940
Completado
Fase 3
ClinicalTrials.gov
A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up
INTERVENTIONAL
Inicio: 1 de feb de 2006
ID: NCT00308308
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)
INTERVENTIONAL
Inicio: 2 de dic de 2013
ID: NCT01885208
Completado
Fase 3
ClinicalTrials.gov
A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 20 de mar de 2018
ID: NCT03429543
Completado
Fase 2
ClinicalTrials.gov
Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
INTERVENTIONAL
Inicio: 1 de feb de 2006
ID: NCT00296374
Completado
Fase 3
ClinicalTrials.gov
NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)
INTERVENTIONAL
Inicio: 1 de feb de 2010
ID: NCT01074268
Completado
Fase 1
ClinicalTrials.gov
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
INTERVENTIONAL
Inicio: 1 de may de 2008
ID: NCT00562250
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
INTERVENTIONAL
Inicio: 1 de ago de 2011
ID: NCT01422876
Terminado
Fase 3
ClinicalTrials.gov
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
INTERVENTIONAL
Inicio: 1 de abr de 2009
ID: NCT00900146
Completado
Fase 3
ClinicalTrials.gov
The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00388726
Completado
Fase 4
ClinicalTrials.gov
Evaluation of Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart or Insulin NPH in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 3 de dic de 2003
ID: NCT00592969
Anterior
1
...
22
23
24
...
35
Siguiente
Filtros